eamdacademy.org-tM4h-1789536430-l990234093 1789536430 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2026 5 2 Giulia Romano Marco Bianchi Paolo Conti 2026 10.68159/l990234093 https://eamdacademy.org/pub/journal/3/article/l990234093 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. Chu QS. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Ther Adv Med Oncol. 2020;12:1758835919895756. Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, et al. Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives. Cancers (Basel). 2020;12(5):1196. De Mello RA, Neves NM, Tadokoro H, Amaral GA, Castelo-Branco P, Zia VAA. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives. J Clin Med. 2020;9(11):3543. Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179-89. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217-37. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-53. Mohan A, Garg A, Gupta A, Sahu S, Choudhari C, Vashistha V, et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India. 2020;37(3):190-7. Wang L, Sheng Z, Zhang J, Song J, Teng L, Liu L, et al. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. J Chemother. 2022;34(2):87-96. Xu H, Ma D, Yang G, Li J, Hao X, Xing P, et al. Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment. Chin J Cancer Res. 2019;31(2):349-56. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-77. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(22):2251-8. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-64. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-Positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091-08. Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409-16. Huber RM, Hansen KH, Paz-Ares Rodriguez L, West HL, Reckamp KL, Leighl NB, et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-Year follow-up on systemic and intracranial outcomes in the Phase 2 ALTA trial. J Thorac Oncol. 2020;15(3):404-15. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654- 67. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012;4(120):120ra117. Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, et al. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol. 2018;29(9):1964-71. Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Differential crizotinib response duration among ALK fusion variants in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(28):3383-9. Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, et al. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. Korean J Intern Med. 2019;34(5):1116-24.